Editas Medicine SVP Parison Amy Sells 679 Shares at $2.58/Share.

Editas Medicine, Inc. [EDIT] has recently announced that Parison Amy, the company's Senior Vice President and Chief Financial Officer, has sold 679 shares at a price of $2.58 per share on August 7, 2025.

Editas Medicine Inc. [EDIT], a clinical stage genome editing company, has recently seen its Senior Vice President and Chief Financial Officer, Parison Amy, sell 679 shares of the company's stock. The transaction took place on August 7, 2025, with each share sold at a price of $2.58. This sale follows a trend of insider activity within the company, with recent reports indicating significant share sales by executives [1].

The total proceeds from the sale amount to $1,761.42. As of the most recent SEC filings, Amy owns 280,282 shares of Editas Medicine, valued at approximately $482,085.04 [1]. The stock has been trading at $2.44 per share, with a market capitalization of $204.25 million as of July 30, 2025 [2].

Editas Medicine has been in the spotlight due to its gene-editing platform based on CRISPR technology, focusing on developing transformative genomic medicines for serious diseases. The company's pipeline includes EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis, and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia [3].

The company is expected to announce its Q2 2025 earnings on August 6th, with analysts expecting a loss of ($0.40) per share and revenue of $1.81 million. The stock has seen various analysts adjusting their ratings, with a consensus target price of $4.70 [2].

References:
[1] https://www.marketbeat.com/instant-alerts/editas-medicine-edit-expected-to-announce-earnings-on-wednesday-2025-07-30/
[2] https://www.tradingview.com/news/tradingview:56a1995dbb832:0-editas-medicine-evp-sells-shares-to-meet-tax-obligations/
[3] https://www.gurufocus.com/news/3044236/achieve-life-sciences-reports-second-quarter-2025-financial-results-provides-updates-on-cytisinicline-program-achv-stock-news